adverse event reporting

Gene editing CRISPR gene therapy
Biotech

After 2 undisclosed deaths, can China’s IIT still be trusted?

Seeing the deaths as proof that the investigator-initiated trials (IIT) pathway is unreliable ignores new guardrails added by China, experts told Fierce.
Angus Liu , Darren Incorvaia Aug 17, 2026 7:20am
FDA Building 2

FDA stops Kura's early-phase leukemia trial after patient dies

Nov 24, 2021 9:55am
stethoscope listen lung

Turning Point shares slide on 82% NSCLC ORR

Jun 3, 2019 9:46am
FDA

FDA ends program hiding reports of faulty medical devices

May 6, 2019 8:06am
FDA

FDA details spike in breast implant-associated cancer reports

Feb 7, 2019 5:02pm
Bayer

Bayer dismisses Essure concerns as safety, legal claims mount

Jul 27, 2018 11:35am